Pharmaceutical Technology

DECEMBER 11, 2022

Richter’s transformation (RT) is a rare blood cancer arising in up to 10% of patients with chronic lymphocytic leukemia (CLL) and presenting as aggressive lymphoma, typically as diffuse large B-cell lymphoma (DLBCL). Among the enrolled patients, 68 were previously treated and seven were newly diagnosed. The mOS was 13.1

FDA 59

FDA Patients Safety Pharmaceutical 59

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

AUGUST 22, 2022

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. billion by 2028, at a CAGR of 12.6%.

Prescription 52

Prescription Safety Patients Pharmaceutical 52

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

Marketing 59

Marketing Side effects Sales Safety 59

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Pharmaceutical Technology

FEBRUARY 13, 2023

GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. All patients had received CDK4/6 inhibitors, and 79% had received AstraZeneca’s ER non-PROTAC degrader Faslodex (fulvestrant). Among 44 patients with measurable disease, two had confirmed partial responses.

Competition 59

Competition Safety Patients Pharmaceutical 59

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Edward helps clients with compliance and safety issues, including in the development, launch and marketing of new products. of the MDR and Article 110.4

Medical 117

Medical Government Marketing Medicine 117

Pharmaceutical Technology

OCTOBER 28, 2022

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. billion and $812 million in 2028. The company expects to hold regulatory talks to shape its incoming Phase III program in adult patients in the second half of 2023.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Technology

AUGUST 24, 2022

CAGR between 2020 and 2028. Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. FCM provides the data to help researchers identify potential biomarkers to better understand why certain patients develop resistance to a therapy. The importance of validation.

Transportation 52

Transportation Patients Marketing Safety 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients.

Marketing 52

Marketing FDA Competition Medical 52

Contrarian Sales Techniques

FEBRUARY 10, 2023

They are designed to be safe and comfortable for patients, and typically have minimal side effects. According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

European Pharmaceutical Review

FEBRUARY 14, 2023

Robust analytical methods are needed to establish safety, potency, and purity of mRNA therapeutics in large-scale manufacturing. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

Food and Drug Administration 105

Food and Drug Administration Medicine Safety Manufacturing 105

European Pharmaceutical Review

OCTOBER 12, 2023

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Subject to planning permission, the site is expected to be opened by 2028.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104